The 340B drug discount program—and congressional activity associated with it—remained a hot topic for lobbyists in the first three months [...] …
Blog Posts
Following the recent death of former Arkansas governor and U.S. Sen. David Pryor, he is being remembered for his important [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
SPONSORED CONTENT
Attention 340B Covered Entities: For most covered entities, the 340B program is essential to their organization’s bottom line – so protecting it becomes necessary. 340B program risks are numerous and often not fully recognized. Duplicate discounts, diversion, and poor documentation are common findings from a HRSA audit. People and processes are often insufficient to fully recognize and address compliance risks. At the same time, lawmakers at the federal and state levels are increasing attention on ensuring that providers are good program stewards.
340B program managers should employ multiple strategies to ensure effective risk management programs are in place. Automation and technology tools can enable a comprehensive approach to managing compliance risk. Processes can fail, and people can miss critical compliance elements, but technology mitigates the gaps in risk management.
This webinar will emphasize how non-compliance is not an option, examine the benefit of a proactive compliance approach vs. a reactive one, and
…
Attorneys for both covered entities and drug manufacturers say they expect a significant number of filings to the newly re-established [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
A drug industry vendor and a conservative non-profit each urged a full federal appeals court to rehear a case on [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
The state agency tasked with implementing Maine’s state 340B hospital reporting requirement has proposed a rule with additional data and [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Thousands of covered entities that purchased more than one hundred Novartis products between late 2019 and early 2023 will be [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
After over 30 years of working in Washington, D.C., I have become accustomed to the expression “politics ain’t beanbag.” The [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Provider advocates celebrated—with some reservations—the recently issued final rule reshaping the Administrative Dispute Resolution (ADR) process for 340B stakeholders. On [...] …
Please Login or Become a Paid Subscriber to View this Content
If you are already a
Sen. John Thune (R-S.D.), who is spearheading a major bipartisan 340B reform package, told hospital executives Tuesday that 340B legislation [...] …